PATENT CLAIM ANALYSIS

Application Number: 16226175
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["424", "153100"]

Abstract:
The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.

Claim (Index 31):
The method of  claim 30 , wherein the PD-1/PDL-1 pathway inhibitor agent is selected from pembrolizumab, avelumab, atezolizumab (MPDL3280A), nivolumab (BMS-936558), pidilizumab (MK-3475), MSB0010718C, and MEDI4736.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.125
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15524844', '15113154', '15213829', '15645544', '14771817']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7528444883853338
- 35 USC 102 Novelty (BERT): 0.6222774850490502
- Combined Prediction Score: 0.7397877880517054
- Mean Citation Score: 346.191074
- Max Citation Score: 630.56506
- Similarity Product: 499.8012987352562

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test